About
Small molecules for neuro / psychiatric disorders
Areas of Focus
Categories
Small Molecule PharmaceuticalVirginia, DC, DE & Maryland
Team (18)
Aaron Kantoff
Avalo Therapeutics
team_member
Ashley Ivanowicz
Senior Vice President, Human Resources
Avalo Therapeutics
executive
Chris Sullivan
Chief Financial Officer
Avalo Therapeutics
executive
Colleen Matkowski
Senior Vice President, Global Regulatory Affairs and Quality Assurance
Avalo Therapeutics
executive
Dino C. Miano, PhD
Senior Vice President, CMC and Technical Operations
Avalo Therapeutics
executive
Garry A. Neil, MD
Chief Executive Officer
Avalo Therapeutics
executive
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
10
As Collaborator
0
Total Enrollment
2,137
By Phase
PHASE2: 6PHASE1: 4
By Status
COMPLETED: 7RECRUITING: 1WITHDRAWN: 1TERMINATED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06603077Lead Sponsor
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
PHASE2Recruiting
222 participants
Started: Sep 16, 2024 · Completed: Jul 31, 2026
NCT05288504Lead Sponsor
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
PHASE2Completed
91 participants
Started: Feb 24, 2022 · Completed: May 11, 2023
NCT04994002Lead Sponsor
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
PHASE1Withdrawn
Started: Sep 3, 2021 · Completed: Jun 30, 2022
NCT04671251Lead Sponsor
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
PHASE1Completed
13 participants
Started: Dec 15, 2020 · Completed: Mar 30, 2022
NCT03169894Lead Sponsor
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
PHASE1Terminated
8 participants
Started: Jul 14, 2017 · Completed: Oct 12, 2021
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...